In summary, this study illustrates the pharmacological mechanism of paeonol, the main active ingredient of JJHYD, on treating CHF, which specifically targets GSK3A to inhibit the PPARα pathway to prevent cardiac lipid accumulation. Here, PPARA is linked to congestive heart failure.